Femasys Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
FEMY Nasdaq 3840 www.femasys.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Femasys Inc.

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment - Jan 16th, 2025 1:30 pm
Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed - Dec 3rd, 2024 2:00 pm
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment - Nov 26th, 2024 1:30 pm
Femasys Third Quarter 2024 Earnings: Misses Expectations - Nov 15th, 2024 11:19 am
Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates - Nov 12th, 2024 2:45 pm
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update - Nov 12th, 2024 1:30 pm
Femasys to Exhibit at the Annual AAGL 2024 Global Conference - Nov 7th, 2024 1:30 pm
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control - Nov 1st, 2024 12:30 pm
Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed - Oct 30th, 2024 1:00 pm
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program - Oct 10th, 2024 12:30 pm
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - Oct 8th, 2024 12:30 pm
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments - Oct 2nd, 2024 12:30 pm
Femasys Announces Infertility Clinic Customers from Coast to Coast - Sep 18th, 2024 12:30 pm
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market - Sep 11th, 2024 12:30 pm
Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device - Sep 10th, 2024 2:41 pm
FDA clears FemChec for fallopian tube occlusion testing - Sep 9th, 2024 3:53 pm
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check - Sep 9th, 2024 12:30 pm
Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting - Sep 5th, 2024 12:30 pm
Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI - Sep 3rd, 2024 1:43 pm
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference - Sep 3rd, 2024 12:30 pm